Alnylam, Provectus and Cellceutix News
I haven't written a lot about Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) lately, in large part because the company is so heavily invested in research, thanks to early enthusiasm over the potential of RNA interference. It's also the most visible of the RNAi companies, with a relatively large capitalization of more than half a billion dollars and a healthy trading volume. Traders have a large impact on this company's stock, and the ongoing sorting out of intellectual property rights has made the company impossible to predict.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.